UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3154-3159

2010

Volltextzugriff (PDF)

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4040-4040

2024

Volltextzugriff (PDF)

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.306-306

2024

Volltextzugriff (PDF)

Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11547-11547

2022

Volltextzugriff (PDF)

Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11509-11509

2023

Volltextzugriff (PDF)

Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8540-8540

2022

Volltextzugriff (PDF)

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.719-719

2018

Volltextzugriff (PDF)

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.TPS213-TPS213

2017

Volltextzugriff (PDF)

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.TPS192-TPS192

2018

Volltextzugriff (PDF)

CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4132-TPS4132

2017

Volltextzugriff (PDF)

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2016-06, Vol.34 (18_suppl), p.LBA5503-LBA5503

2016

Volltextzugriff (PDF)

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.LBA5503-LBA5503

2016

Volltextzugriff (PDF)

FDG-PET in the staging and prognosis of T-cell lymphoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18502-e18502

2011

Volltextzugriff (PDF)

Prognostic factors for survival after embolization of hepatic metastases in uveal melanoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8562-8562

2007

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektionJournals@Ovid Complete

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649

Circulating tumor DNA (ctDNA) detection of molecular residual disease (MRD) as a potential biomarker in localized soft tissue sarcoma (STS)

Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS)

Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer

CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)

FDG-PET in the staging and prognosis of T-cell lymphoma

Prognostic factors for survival after embolization of hepatic metastases in uveal melanoma

Aktive Filter

Suchergebnisse filtern